Dxcover Limited appoints Operations Director as it targets further growth

Dxcover Limited appoints Operations Director as it targets further growth

Dxcover Limited has appointed experienced diagnostics industry professional Dr David Eustace as Operations Director to drive product development, manufacturing, regulatory and laboratory operations. 

Dr Eustace’s appointment comes following a period of substantial growth for the Strathclyde University spin out, which is developing blood tests for early detection of cancer. In 2021, Dxcover has completed its second clinical study, showcasing the clinical utility of the Dxcover® Brain Cancer test, and recently moved into new lab and office space in Glasgow’s Innovation District in preparation for further growth. 

Dr Eustace joins the team from Bruker Daltonics, the American-owned scientific instruments and diagnostics company, where he worked as Operations Director in Germany and Scotland. Since finishing a PhD at the University of Glasgow and postdoctoral studies at Imperial College, Dr Eustace has gained 13 years’ experience in the industry, working for Renishaw Diagnostics, Bruker Molecular Testing and most recently the Bruker Covid-19 response projects at its plant in Germany.

Dr Eustace, newly appointed Operations Director at Dxcover Limited, commented: “The Covid-19 pandemic has heightened the need for quicker and more effective diagnostic tests to help healthcare professionals triage patients effectively and make sure that the best possible care is delivered as quickly as possible. Earlier cancer diagnoses result in significantly higher survival rates and the Dxcover team has been making huge steps to translate groundbreaking technology into the clinic to make that possible”.

“I am honoured to be joining such a talented team, dedicated to saving more lives, and look forward to taking the Dxcover® Brain Cancer liquid biopsy through the next level of clinical and regulatory approvals which are required prior to commercial use.” 

Since spin-out in 2019, Dxcover has raised £5.1m in funding to progress its multi-cancer development program, the Dxcover® Cancer Project. Dxcover’s liquid biopsy technology is fast, inexpensive, and only requires a blood sample to be taken and sent to the lab for analysis with infra-red light. Dxcover’s ‘drop, dry, detect’ technology provides results in minutes and is powered by artificial intelligence to detect the signs of cancer.

Dr Mark Hegarty, CEO, Dxcover Limited, said: “The appointment of David marks a significant step in the growth of the Dxcover business and we are thrilled to attract such a high calibre professional and industry leader to our growing team. His track record speaks for itself, and his sector-specific knowledge and experience will be of great value as we accelerate our regulatory and clinical plans.”

For more information on Dxcover, please visit: www.dxcover.com